Physician profile
Daniel Maxwell Mclean
NPI 1083955090
$4,126.41
in general payments reported to CMS, 2019-2025
29 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $80.17 · 2023: $812 · 2024: $1,329 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,046.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,059.12 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $503.07 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $378.89 | 2023-2025 | |
| Abbvie INC. | $356.05 | 2023-2025 | |
| Amgen INC. | $280.67 | 2023-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $252.31 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $221.82 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $149.51 | 2023-2025 | |
| Exact Sciences Corporation | $111.13 | 2023-2025 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $108.55 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $85.43 | 2022-2025 | Eliquis |
| Phathom Pharmaceuticals, INC. | $81.34 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $57.06 | 2025 | Korlym |
| Abbott Laboratories | $52.44 | 2023-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.79 | 2025 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.62 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.35 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $42.48 | 2022-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $35.06 | 2025 | Zoryve |
| Viatris Specialty LLC | $31.10 | 2025 | Yupelri |
| Mylan Specialty L.P. | $26.40 | 2024 | Yupelri |
| Lucid Diagnostics INC. | $23.31 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.37 | 2023 | Jardiance |
| Azurity Pharmaceuticals, INC. | $21.88 | 2024 | Horizant |
| Takeda Pharmaceuticals U.S.A., INC. | $20.85 | 2024 | Trintellix |
| Exeltis, USA INC. | $20.63 | 2025 | Slynd |
| Astellas Pharma US INC | $17.34 | 2025 | Veozah |
| Alexion Pharmaceuticals, INC. | $17.03 | 2025 | Strensiq |
| Medline Industries LP | $13.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.